Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-35 (canceled)

Claim 36 (currently amended): A method of treating a human patient suffering from a disease or condition, comprising administering to a patient in need thereof a pharmaceutical composition ~~at a monthly dose of about 1.0 mg up to about 15 mg of paclitaxel/kg body weight of the patient, wherein the dose for a single administration is between 0.275 and 1.65 mg of paclitaxel/kg body weight of the patient, and wherein the pharmaceutical composition comprises~~comprising a cationic liposomal preparation comprising at least one cationic lipid from about 30 mole% to about 99.9 mole%, paclitaxel in an amount of at least about 0.1 mole% and at least one neutral and/or anionic lipid from about 0 mole% to about 70 mole%, wherein the amount of paclitaxel in a single dose of the pharmaceutical composition is between about 0.275 and about 1.65 mg/kg body weight of the patient.

Claims 37-43 (canceled)

Claim 44 (currently amended): A method of treating a human patient suffering from a disease or condition with a combination therapy, comprising administering to a patient in need thereof a pharmaceutical composition ~~at a monthly dose of about 1.0 mg up to about 15 mg of paclitaxel/kg body weight of the patient, wherein the dose for a single administration is between 0.275 and 1.65 mg of paclitaxel/kg body weight of the patient, and wherein the pharmaceutical composition comprises~~comprising a cationic liposomal preparation comprising at least one cationic lipid from about 30 mole% to about 99.9 mole%, paclitaxel in an amount of at least about 0.1 mole% and at least one neutral and/or anionic lipid from about 0 mole% to about 70 mole%, wherein the amount of paclitaxel in a single dose of the pharmaceutical composition is between about 0.275 and about 1.65 mg/kg body weight of the patient, and wherein the pharmaceutical composition is administered simultaneously, separately, or sequentially with an effective dose of at least one further active agent and/or heat and/or radiation and/or cryotherapy.

Claim 45 (currently amended): The method of claim 44, wherein the pharmaceutical composition is administered simultaneously with an effective dose of at least one further active agent.

Claim 46 (previously presented): The method of claim 36, wherein the cationic liposomal preparation comprises paclitaxel in an amount of at least about 2 mole% to about 8 mole%.

Claim 47 (previously presented): The method of claim 36, wherein the cationic liposomal preparation comprises paclitaxel in an amount of about 2.5 mole% to about 3.5 mole%.

Claim 48 (previously presented): The method of claim 36, wherein the cationic liposomal preparation comprises 50:47:3 mole% of DOTAP, DOPC and paclitaxel.

Claim 49 (previously presented): The method of claim 36, wherein the cationic liposomal preparation comprises substantially no paclitaxel crystals.

Claim 50 (previously presented): The method of claim 36, wherein the condition is an angiogenesis-associated condition.

Claim 51 (previously presented): The method of claim 50, wherein the disease or condition is selected from the group consisting of cancer, rheumatoid arthritis, dermatitis, psoriasis, and endometriosis.

Claim 52 (currently amended): A method of treating or preventing a disorder associated with and/or accompanied by occurrence of drug resistant cells, comprising administering to a patient in need thereof a pharmaceutical composition ~~at a monthly dose of about 1.0 mg up to about 15 mg of paclitaxel/kg body weight of the patient, wherein the dose for a single administration is between 0.275 and 1.65 mg of paclitaxel/kg body weight of the patient, and~~

~~wherein the pharmaceutical composition comprises~~comprising at least one cationic lipid from about 30 mole% to about 99.9 mole%, paclitaxel in an amount of at least about 0.1 mole% and at least one neutral and/or anionic lipid from about 0 mole% to about 70 mole%, wherein the amount of paclitaxel in a single dose of the pharmaceutical composition is between about 0.275 and about 1.65 mg/kg body weight of the patient.

Claim 53 (previously presented): The method of claim 52, wherein the method is a second or third line treatment for cancer.

Claim 54 (previously presented): The method of claim 52, wherein the cationic liposomal preparation comprises 50:47:3 mole% of DOTAP, DOPC, and paclitaxel.

Claim 55 (currently amended): A method of treating or preventing metastasis formation in a human patient, comprising administering a pharmaceutical composition ~~at a monthly dose of about 1.0 mg up to about 15 mg of paclitaxel/kg body weight of the patient, wherein the dose for a single administration is between 0.275 and 1.65 mg of paclitaxel/kg body weight of the patient, and wherein the pharmaceutical composition comprises~~comprising a cationic liposomal preparation comprising at least one cationic lipid from about 30 mole% to about 99.9 mole%, paclitaxel in an amount of at least about 0.1 mole% and at least one neutral and/or anionic lipid from about 0 mole% to about 70 mole%, wherein the amount of paclitaxel in a single dose of the pharmaceutical composition is between about 0.275 and about 1.65 mg/kg body weight of the patient.

Claim 56 (previously presented): The method of claim 55, wherein the method treats or prevents liver metastasis formation.

Claim 57 (currently amended): A method of treating a human patient with a combination therapy, comprising administering to a patient in need thereof, a pharmaceutical composition ~~at a monthly dose of about 1.0 mg up to about 15 mg of paclitaxel/kg body weight of the patient, wherein the dose for a single administration is between 0.275 and 1.65 mg of paclitaxel/kg body weight of the patient, and wherein the pharmaceutical composition comprises~~comprising a

cationic liposomal preparation comprising at least one cationic lipid from about 30 mole% to about 99.9 mole%, paclitaxel in an amount of at least about 0.1 mole% and at least one neutral and/or anionic lipid from about 0 mole% to about 70 mole% ~~for manufacturing a pharmaceutical composition~~, wherein the amount of paclitaxel in a single dose of the pharmaceutical composition is between about 0.275 and about 1.65 mg/kg body weight of the patient, and wherein the pharmaceutical composition is administered simultaneously, separately, or sequentially with an effective dose of at least one further active agent and/or heat and/or radiation and/or cryotherapy against metastasis onset and/or progression associated with and/or accompanied by ~~the~~ tumors.

Claim 58 (currently amended): The method of claim 57, wherein the pharmaceutical composition is administered simultaneously with an effective dose of at least one further active agent.

Claim 59 (currently amended): The method of claim 58, wherein the further active agent is ~~selected from the group consisting of a cytotoxic or cytostatic substance~~ a chemotherapeutic agent ~~and an immunological active substance~~.

Claim 60 (previously presented): The method of claim 55, wherein the cationic liposomal preparation comprises 50:47:3 mole% of DOTAP, DOPC, and paclitaxel.

Claims 61-63 (canceled)

Claim 64 (withdrawn/currently amended): The method of claim ~~62~~88, wherein the compound that reduces or eliminates hypersensitivity reactions is selected from the group consisting of steroids, antihistamines, H2 receptor antagonists, and combinations thereof in a sufficient amount to prevent fatal anaphylactic reactions.

Claim 65 (withdrawn/currently amended): The method of claim ~~63~~64, wherein the compound is selected from the group consisting of Ranitidine, Dexamethasone,

Diphenhydramine, Famotidine, Hydrocortisone, Clemastine, Cimetidine, Prednisolone, Chlorpheniramine, Chlorphenamine, Dimethindene maleate, and Promethazine.

Claim 66 (withdrawn/currently amended): The method of claim ~~62~~88, wherein the ~~chemosensitizier~~ chemosensitizer is selected from the group consisting of cell cycle modulators, substances that revert a drug resistance like verapamil, vasoactive substances like anti-hypertensive drugs, and substances that modify interactions of cationic liposomes with blood components like protamine.

Claim 67 (previously presented): The method of claim 36 for the treatment of cancer, wherein the disease is selected from the group consisting of pancreatic cancer, inoperable pancreatic cancer, gastro-intestinal cancer, lung cancer, colorectal or gastric cancer, breast cancer, prostate cancer, and melanoma.

Claim 68 (currently amended): The method of claim 36, wherein the cationic liposomal preparation comprises liposomes having an average particle diameter from about 25 nm to about 500 nm, ~~preferably~~ or about 100 nm to about 300 nm.

Claim 69 (currently amended): The method of claim 36, wherein the ~~cationic liposomal preparation~~pharmaceutical composition is administered intravenously.

Claims 70 and 71 (canceled)

Claim 72 (previously presented): The method of claim 36, wherein the cationic liposomal preparation comprises at least one neutral and/or anionic lipid from about 1 mole% to about 70 mole%.

Claim 73 (previously presented): The method of claim 44, wherein the cationic liposomal preparation comprises at least one neutral and/or anionic lipid from about 1 mole% to about 70 mole%.

Claim 74 (previously presented): The method of claim 52, wherein the cationic liposomal preparation comprises at least one neutral and/or anionic lipid from about 1 mole% to about 70 mole%.

Claim 75 (previously presented): The method of claim 55, wherein the cationic liposomal preparation comprises at least one neutral and/or anionic lipid from about 1 mole% to about 70 mole%.

Claim 76 (previously presented): The method of claim 57, wherein the cationic liposomal preparation comprises at least one neutral and/or anionic lipid from about 1 mole% to about 70 mole%.

Claims 77-79 (canceled):

Claim 80 (new): The method of claim 59, wherein the chemotherapeutic agent is selected from the group consisting of a cytotoxic or cytostatic compound, an anti-tumor active agent, an immunological active agent, an antineoplastic agent, and a chemosensitizer.

Claim 81 (new): The method of claim 80, wherein the anti-tumor active agent is an anti-endothelial cell active agent.

Claim 82 (new): The method of claim 80, wherein the immunological active agent is a compound that reduces or eliminates hypersensitivity reactions.

Claim 83 (new): The method of claim 80, wherein the antineoplastic agent is an antimitotic agent.

Claim 84 (new): The method of claim 83, wherein the antimitotic agent is selected from the group consisting of cisplatin, carboplatin, camptothecin doxorubicin, 5-fluorouracil, and gemcitabine.

Claim 85 (new): The method of claim 44, wherein the further active agent is a chemotherapeutic agent.

Claim 86 (new): The method of claim 85, wherein the chemotherapeutic agent is selected from the group consisting of a cytotoxic or cytostatic compound, an anti-tumor active agent, an immunological active agent, an antineoplastic agent, and a chemosensitizer.

Claim 87 (new): The method of claim 86, wherein the anti-tumor active agent is an anti-endothelial cell active agent.

Claim 88 (new): The method of claim 86, wherein the immunological active agent is a compound that reduces or eliminates hypersensitivity reactions.

Claim 89 (new): The method of claim 86, wherein the antineoplastic agent is an antimitotic agent.

Claim 90 (new): The method of claim 89, wherein the antimitotic agent is selected from the group consisting of cisplatin, carboplatin, camptothecin doxorubicin, 5-fluorouracil, and gemcitabine.